A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients (PRESERVE)
A 2-year, Single-arm, Multi-center Study to Explore the Efficacy and Safety of Pegcetacoplan in Preventing Disease Recurrence in Adolescent and Adult Kidney Transplant Recipients With C3 Glomerulopathy or Primary Immune-complex Membranoproliferative Glomerulonephritis
To assess the efficacy and safety of pegcetacoplan for the prevention of recurrent C3G or primary IC-MPGN in kidney transplant recipients
調査の概要
状態
条件
介入・治療
詳細な説明
The PRESERVE study is a Phase 3b, multicenter, single-arm, open-label clinical trial designed to explore the efficacy and safety of pegcetacoplan in preventing or delaying the recurrence of C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) following kidney transplantation. Recurrence of these diseases after transplantation is common and can lead to graft dysfunction and loss. Pegcetacoplan is a complement C3/C3b inhibitor that has demonstrated activity in patients with native kidney disease and recurrent disease after transplantation. The study aims to assess whether initiating pegcetacoplan at the time of kidney transplantation, before recurrence occurs, may delay the recurrence and support long-term graft outcomes. Participants will receive pegcetacoplan in addition to standard post-transplant care and will be followed to evaluate disease recurrence, kidney function, graft outcomes, safety, and tolerability.
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Study Physician
- 電話番号:+46 86972000
- メール:medical.info@sobi.com
研究場所
-
-
Greater London
-
London、Greater London、イギリス、NW3 2QG
- Royal Free Hospital
-
London、Greater London、イギリス、W12 0HS
- Hammersmith Hospital
-
-
Greater Manchester
-
Manchester、Greater Manchester、イギリス、M13 9WL
- Manchester Royal Infirmary
-
-
Tyne & Wear
-
Newcastle upon Tyne、Tyne & Wear、イギリス、NE7 7DN
- Freeman Hospital
-
-
-
-
Bari
-
Bari、Bari、イタリア、70124
- Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari
-
-
Bergamo
-
Bergamo、Bergamo、イタリア、24127
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
-
-
Roma
-
Roma、Roma、イタリア、165
- Ospedale Pediatrico Bambino Gesù
-
Roma、Roma、イタリア、168
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
-
-
-
-
Alberta
-
Edmonton、Alberta、カナダ、T6G 2R7
- University of Alberta - Faculty of Medicine & Dentistry
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V6Z 1Y6
- St. Paul's Hospital
-
-
Ontario
-
London、Ontario、カナダ、N6A 5A5
- London Health Sciences Centre (LHSC) - University Hospital
-
Toronto、Ontario、カナダ、M5G 2C4
- Toronto General Hospital
-
-
Quebec
-
Montreal、Quebec、カナダ、H4A 3J1
- McGill University Health Centre Research Institute
-
-
-
-
-
Riyadh、サウジアラビア、11211
- King Faisal Specialist Hospital & Research Center
-
-
-
-
-
Lausanne、スイス、1011
- Centre Hospitalier Universitaire Vaudois (CHUV)
-
-
-
-
Barcelona
-
Barcelona、Barcelona、スペイン、8035
- Hospital Universitari Vall d'Hebron - VHIR
-
-
La Coruña
-
A Coruña、La Coruña、スペイン、15006
- Complejo Hospitalario Universitario A Coruña
-
-
Madrid
-
Madrid、Madrid、スペイン、28041
- Hospital Universitario 12 de Octubre
-
-
Málaga
-
Málaga、Málaga、スペイン、29010
- Hospital Regional Universitario de Malaga
-
-
Vizcaya
-
Barakaldo、Vizcaya、スペイン、48903
- Hospital de Cruces
-
-
-
-
Lower Saxony
-
Hanover、Lower Saxony、ドイツ、30625
- Medizinische Hochschule Hannover
-
-
North Rhine-Westphalia
-
Cologne、North Rhine-Westphalia、ドイツ、50937
- Universitaetsklinikum Koeln
-
Essen、North Rhine-Westphalia、ドイツ、45147
- Universitaetsklinikum Essen
-
-
-
-
-
Helsinki、フィンランド、290
- Helsinki University Central Hospital
-
-
-
-
Bas Rhin
-
Strasbourg、Bas Rhin、フランス、67091
- CHU Strasbourg - Nouvel Hôpital Civil
-
-
Haute Garonne
-
Toulouse、Haute Garonne、フランス、31059
- Hopital Rangueil
-
-
Herault
-
Montpellier、Herault、フランス、34000
- Hopital Lapeyronie pt
-
-
Nord
-
Lille、Nord、フランス、59037
- Hopital Claude Huriez - CHU Lille
-
-
Paris
-
Paris、Paris、フランス、75015
- Hôpital Necker - Enfants Malades
-
-
Rhone
-
Lyon、Rhone、フランス、69437
- Hopital Edouard Herriot - CHU Lyon
-
-
-
-
Pernambuco
-
Recife、Pernambuco、ブラジル、52010-010
- Real Hospital Português
-
-
São Paulo
-
Botucatu、São Paulo、ブラジル、18618-970
- UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
-
São Paulo、São Paulo、ブラジル、05403-000
- Hospital das Clinicas da Faculdade de Medicina da USP - HCFMUSP
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male or female patients with a diagnosis of C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) who are planning to undergo kidney transplantation because of the disease.
- Have a high risk of disease recurrence following kidney transplantation, based on either having a previous kidney allograft loss due to recurrence of C3G or primary IC-MPGN, or assessed as having a high risk by the investigator based on other clinical information.
- Is fully vaccinated and up to date with their vaccinations against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B, in accordance with local guidelines, at the time of initiating pegcetacoplan.
Exclusion Criteria:
- A known secondary cause for MPGN, including but not limited to monoclonal gammopathy of clinical significance, hepatitis B, hepatitis C, or autoimmune cryoglobulinemia.
- History of invasive meningococcal disease.
- History of malignancy, except for the following: cured basal or squamous cell skin cancer, curatively treated in situ disease, or currently malignancy-free and has been off-treatment for the malignancy for at least 5 years.
- Hypersensitivity to pegcetacoplan or any of its excipients.
- Known or suspected hereditary fructose intolerance.
- Any other medical condition which, in the opinion of the Investigator, makes the participant unsuitable for inclusion.
- Use of a complement inhibitor for the treatment of C3G or primary IC-MPGN within 1 month prior to the scheduled kidney transplantation surgery.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Pegcetacoplan
Pegcetacoplan, a complement C3/C3b inhibitor, administered according to the study protocol in kidney transplant recipients with high risk of recurring C3G or primary IC-MPGN |
Dose amount based on age and weight Subcutaneous infusion twice-a-week. Adult participants aged 18 years or older at enrolment: 1080 mg Adolescent participants aged 12 to 17 years at enrolment:
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Occurrence of Clinically Significant Recurrent Disease
時間枠:Within 2 years after kidney transplantation
|
Histological evidence of recurrent disease based on the histopathological assessment of the kidney biopsy |
Within 2 years after kidney transplantation
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time to Onset of Clinically Significant Disease Recurrence
時間枠:Up to 2 years after kidney transplantation
|
To explore the impact of pegcetacoplan on time to clinically significant recurrence of C3G or primary IC-MPGN after kidney transplantation |
Up to 2 years after kidney transplantation
|
協力者と研究者
スポンサー
協力者
捜査官
- スタディディレクター:Study Physician、Swedish Orphan Biovitrum AB (publ)
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- Sobi.PEGCET-404
- 2026-526392-39-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Qualified researchers may request access to patient level data and related study documents.
All requests are evaluated by a cross functional panel of experts within Sobi. Patient level data will be anonymized and study documents, if applicable, will be redacted to protect the privacy of trial participants.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。